Premium
Determination of cyclobenzaprine in human plasma by liquid chromatography‐electrospray ionization tandem mass spectrometry and its application in a pharmacokinetic study
Author(s) -
Xiang Yi,
Zhou Liping,
Qian Zhenyu,
Peng Kelong,
Li Dongyan,
Chen Xiaomei,
Jiang Hongliang,
Zheng Heng
Publication year - 2012
Publication title -
biomedical chromatography
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.4
H-Index - 65
eISSN - 1099-0801
pISSN - 0269-3879
DOI - 10.1002/bmc.1751
Subject(s) - chemistry , chromatography , electrospray ionization , pharmacokinetics , liquid chromatography–mass spectrometry , tandem mass spectrometry , mass spectrometry , direct electron ionization liquid chromatography–mass spectrometry interface , ionization , chemical ionization , organic chemistry , pharmacology , ion , medicine
A sensitive, rapid and simple liquid chromatography–electrospray ionization mass spectrometry (LC‐ESI‐MS/MS) method was developed for the quantitative determination of cyclobenzaprine in human plasma, to study the pharmacokinetic behavior of cyclobenzaprine capsule in healthy Chinese volunteers. With escitalopram as the internal standard (IS), sample pretreatment involved a one‐step liquid–liquid extraction using saturated sodium carbonate solution and hexane–diethyl ether (3:1, v/v). The separation was performed on an Ultimate XB‐CN column (150 × 2.1 mm, 5 µm). Isocratic elution was applied using acetonitrile–water (40:60, v/v) containing 10 m M ammonium acetate and 0.1% formic acid. The detection was carried out on a triple‐quadrupole tandem mass spectrometer in multiple reaction monitoring mode via electrospray ionization. The ion‐pairs including m / z 276.2–216.2 for cyclobenzaprine and m / z 325.2–109.1 for IS were used for monitoring. Linear calibration curves were obtained over the range of 0.049–29.81 ng/mL with the lower limit of quantification at 0.049 ng/mL. The intra‐ and inter‐day precision showed ≤6.5% relative standard deviation. The established method laid the groundwork for follow‐up studies and provided basis for the clinical administration of cyclobenzaprine. Copyright © 2011 John Wiley & Sons, Ltd.